{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:37Z","timestamp":1793191777233,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":1617,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1111\/jth.14124","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T15:10:08Z","timestamp":1523977808000},"page":"1055-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Factor\u00a0VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia\u00a0A: a systematic review"],"prefix":"10.1016","volume":"16","author":[{"given":"S.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Gouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.R.","family":"Rosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"van der Bom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14124_bb0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias \u2013 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14124_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1111\/jth.14124_bb0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia\u00a0A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.14124_bb0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia\u00a0A patients treated with plasma\u2010derived or recombinant factor\u00a0VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0030","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor\u00a0VIII and neutralizing antibodies in hemophilia\u00a0A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14124_bb0035","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor\u00a0VIII treatment and inhibitor development in children with severe hemophilia\u00a0A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14124_bb0040","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/jth.12335","article-title":"Inhibitor development in previously treated hemophilia\u00a0A patients: a systematic review, meta\u2010analysis, and meta\u2010regression","volume":"11","author":"Xi","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0045","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/j.1538-7836.2006.02233.x","article-title":"Incidence of inhibitors in a cohort of 838 males with hemophilia\u00a0A previously treated with factor\u00a0VIII concentrates","volume":"4","author":"Kempton","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0050","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/blood-2010-09-308668","article-title":"Incidence of factor\u00a0VIII inhibitors throughout life in severe hemophilia\u00a0A in the United Kingdom","volume":"117","author":"Hay","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.14124_bb0055","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/j.1538-7836.2011.04472.x","article-title":"Can B\u2010domain deletion alter the immunogenicity of recombinant factor\u00a0VIII? A meta\u2010analysis of prospective clinical studies","volume":"9","author":"Aledort","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0060","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2016-11-750885","article-title":"Biological considerations of plasma\u2010derived and recombinant factor\u00a0VIII immunogenicity","volume":"129","author":"Lai","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.14124_bb0065","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta\u2010analysis of observational studies in epidemiology: a proposal for reporting. Meta\u2010analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/jth.14124_bb0070","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1111\/jth.14124_bb0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non\u2010randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"10.1111\/jth.14124_bb0080","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta\u2010analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"10.1111\/jth.14124_bb0085","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta\u2010analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"10.1111\/jth.14124_bb0090","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/jth.14124_bb0095","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2516.2009.02024.x","article-title":"Efficacy and safety evaluation of sucrose\u2010formulated recombinant factor\u00a0VIII for Taiwanese patients with haemophilia\u00a0A","volume":"15","author":"Young","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0100","first-page":"18","article-title":"Data from a prospective post\u2010authorization safety surveillance study in 384 hemophilia\u00a0A patients in Japan with the antihemophilic factor (recombinant) plasma\/albumin\u2010free method demonstrates safety and efficacy","volume":"20","author":"Fukutake","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2516.1999.00191.x","article-title":"Human recombinant DNA\u2010derived antihaemophilic factor (factor\u00a0VIII) in the treatment of haemophilia\u00a0A: conclusions of a 5\u2010year study of home therapy. The KOGENATE Study Group","volume":"5","author":"Seremetis","year":"1999","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0110","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1365-2516.2010.02332.x","article-title":"Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma\/albumin\u2010free method] demonstrates efficacy, safety and low\u2010risk for immunogenicity in routine clinical practice","volume":"16","author":"Oldenburg","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0115","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0037-1613925","article-title":"Sucrose formulated recombinant human antihemophilic factor\u00a0VIII is safe and efficacious for treatment of hemophilia\u00a0A in home therapy \u2013 International Kogenate\u2010FS Study Group","volume":"83","author":"Abshire","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH14-10-0826","article-title":"Inhibitor development in haemophilia according to concentrate. Four\u2010year results from the European HAemophilia Safety Surveillance (EUHASS) project","volume":"113","author":"Fischer","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2004.05058.x","article-title":"Efficacy and inhibitor development in previously treated patients with haemophilia\u00a0A switched to a B domain\u2010deleted recombinant factor\u00a0VIII","volume":"126","author":"Gringeri","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14124_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/hae.12563","article-title":"The incidence of factor\u00a0VIII inhibitors in severe haemophilia\u00a0A following a major switch from full\u2010length to B\u2010domain\u2010deleted factor\u00a0VIII: a prospective cohort comparison","volume":"21","author":"Hay","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0135","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2516.2009.02027.x","volume":"15","author":"Recht","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0140","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hae.12306","article-title":"Patient characteristics that influence efficacy of prophylaxis with rFVIII\u2010FS three times per week: a subgroup analysis of the LIPLONG study","volume":"20","author":"Lalezari","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0145","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1055\/s-0038-1665410","article-title":"A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor\u00a0VIII in the treatment of patients with hemophilia\u00a0A. German Kogenate Study Group","volume":"78","author":"Aygoren\u2010Pursun","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0150","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1055\/s-0038-1656030","article-title":"A multicenter study of recombinant factor\u00a0VIII (Recombinate) in previously treated patients with hemophilia\u00a0A. The Recombinate Previously Treated Patient Study Group","volume":"77","author":"White","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1046\/j.1365-2516.2001.00511.x","article-title":"Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII\u2010FS) in patients with haemophilia\u00a0A: a long\u2010term, multicentre clinical study in Japan","volume":"7","author":"Yoshioka","year":"2001","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2516.2006.01416.x","article-title":"Efficacy, safety and tolerability of recombinant factor\u00a0VIII (REFACTO) in patients with haemophilia\u00a0A: interim data from a postmarketing surveillance study in Germany and Austria","volume":"13","author":"Pollmann","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0165","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1160\/TH07-06-0408","article-title":"Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell\u2010produced to baby hamster kidney cell\u2010produced recombinant factor\u00a0VIII","volume":"98","author":"Singleton","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0170","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1538-7836.2008.03032.x","article-title":"Plasma and albumin\u2010free recombinant factor\u00a0VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients","volume":"6","author":"Blanchette","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0175","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1160\/TH07-06-0409","article-title":"Safety and efficacy of sucrose\u2010formulated full\u2010length recombinant factor\u00a0VIII: experience in the standard clinical setting","volume":"99","author":"Musso","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1160\/TH07-12-0724","article-title":"An observational study of sucrose\u2010formulated recombinant factor\u00a0VIII for Japanese patients with haemophilia\u00a0A","volume":"100","author":"Delumeau","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0185","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1365-2516.2009.02079.x","article-title":"Efficacy assessment of a new clotting factor concentrate in haemophilia\u00a0A patients, including prophylactic treatment","volume":"15","author":"Den Uijl","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1538-7836.2009.03650.x","article-title":"Efficacy and safety of secondary prophylactic vs. on\u2010demand sucrose\u2010formulated recombinant factor\u00a0VIII treatment in adults with severe hemophilia\u00a0A: results from a 13\u2010month crossover study","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0195","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on\u2010demand and prophylaxis treatments in hemophilia\u00a0A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0200","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/hae.12165","article-title":"Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia\u00a0A: safety, efficacy and pharmacokinetics","volume":"19","author":"Kulkarni","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0205","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/hae.12159","article-title":"Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia\u00a0A: safety and efficacy","volume":"19","author":"Lentz","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0210","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel\u2010group trial of routine prophylaxis vs. on\u2010demand treatment with sucrose\u2010formulated recombinant factor\u00a0VIII in adults with severe hemophilia\u00a0A (SPINART)","volume":"11","author":"Manco\u2010Johnson","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/hae.12793","article-title":"Novel, human cell line\u2010derived recombinant factor\u00a0VIII (human\u2010cl rhFVIII; Nuwiq(R)) in adults with severe haemophilia\u00a0A: efficacy and safety","volume":"22","author":"Lissitchkov","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0220","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1160\/TH14-09-0760","article-title":"Prospective surveillance study of haemophilia\u00a0A patients switching from moroctocog alfa or other factor\u00a0VIII products to moroctocog alfa albumin\u2010free cell culture (AF\u2010CC) in usual care settings","volume":"114","author":"Parra Lopez","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0225","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3349\/ymj.2015.56.4.935","article-title":"Efficacy, safety, and pharmacokinetics of beroctocog alfa in patients previously treated for hemophilia\u00a0A","volume":"56","author":"Hyun","year":"2015","journal-title":"Yonsei Med J"},{"key":"10.1111\/jth.14124_bb0230","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/hae.12631","article-title":"Real\u2010life evidence in evaluating effectiveness of treatment in haemophilia\u00a0A with a recombinant FVIII concentrate: a non\u2010interventional study in emerging countries","volume":"21","author":"Gouider","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0235","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jth.12828","article-title":"Prophylaxis vs. on\u2010demand treatment with BAY\u00a081\u20108973, a full\u2010length plasma protein\u2010free recombinant factor\u00a0VIII product: results from a randomized trial (LEOPOLD II)","volume":"13","author":"Kavakli","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0240","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hae.12866","article-title":"BAY\u00a081\u20108973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia\u00a0A: results of the LEOPOLD Kids Trial","volume":"22","author":"Ljung","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0245","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/hae.12859","article-title":"Prophylaxis vs. on\u2010demand treatment with Nuwiq((R)) (Human\u2010cl rhFVIII) in adults with severe haemophilia\u00a0A","volume":"22","author":"Tiede","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0250","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1111\/hae.12990","article-title":"Interim results from a large multinational extension trial (guardian( ) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia\u00a0A","volume":"22","author":"Lentz","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0255","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/hae.12952","article-title":"Efficacy and safety of BAY\u00a081\u20108973, a full\u2010length recombinant factor\u00a0VIII: results from the LEOPOLD\u00a0I trial","volume":"22","author":"Saxena","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0260","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/hae.13251","article-title":"PK\u2010guided personalized prophylaxis with Nuwiq(R) (human\u2010cl rhFVIII) in adults with severe haemophilia\u00a0A","volume":"23","author":"Lissitchkov","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14124_bb0265","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V81.8.2180.2180","article-title":"A sudden increase in factor\u00a0VIII inhibitor development in multitransfused hemophilia\u00a0A patients in The Netherlands. Dutch Hemophilia Study Group","volume":"81","author":"Rosendaal","year":"1993","journal-title":"Blood"},{"key":"10.1111\/jth.14124_bb0270","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V71.2.344.344","article-title":"The natural history of factor\u00a0VIII:C inhibitors in patients with hemophilia\u00a0A: a national cooperative study. II. Observations on the initial development of factor\u00a0VIII:C inhibitors","volume":"71","author":"McMillan","year":"1988","journal-title":"Blood"},{"key":"10.1111\/jth.14124_bb0275","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.1990.tb06370.x","article-title":"Haemophiliacs with factor\u00a0VIII inhibitors in Finland: prevalence, incidence and outcome","volume":"76","author":"Rasi","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14124_bb0280","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1538-7836.2004.00710.x","article-title":"The incidence of factor\u00a0VIII and factor\u00a0IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977\u201399","volume":"2","author":"Darby","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14124_bb0285","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/sim.6844","article-title":"Low\u2010event\u2010rate meta\u2010analyses of clinical trials: implementing good practices","volume":"35","author":"Shuster","year":"2016","journal-title":"Stat Med"},{"key":"10.1111\/jth.14124_bb0290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1055\/s-0036-1581102","article-title":"Safety of switching factor\u00a0VIII products in the era of evolving concentrates: myths and facts","volume":"42","author":"Coppola","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.14124_bb0295","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor\u00a0VIII products and inhibitor development in severe hemophilia\u00a0A","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14124_bb0300","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/jth.13382","article-title":"Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH","volume":"14","author":"Iorio","year":"2016","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622011102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622011102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:22:25Z","timestamp":1761535345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622011102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1538783622011102"],"URL":"https:\/\/doi.org\/10.1111\/jth.14124","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor\u00a0VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia\u00a0A: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}